Zydus Lifesciences Limited has recently informed exchanges that the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. This topical anaesthetic is used for local analgesia on normal intact skin and genital mucous membranes, aiding in minor surgeries and as a pretreatment for infiltration anaesthesia. The cream will be produced at Zydus’ manufacturing facility in Changodar, Ahmedabad.
Lidocaine and Prilocaine Cream has seen annual sales of USD 22.05 million in the U.S. market, according to IQVIA data (MAT October 2024). This approval adds to Zydus’ growing portfolio, with the company now holding 412 USFDA approvals and over 473 ANDA filings since 2003-04.
Zydus’ expertise in providing high-quality pharmaceutical products continues to meet global healthcare needs, expanding its footprint in the U.S. market while improving patient access to essential treatments.
In the meantime, Zydus Lifesciences shares opened today at ₹968.05, with a high of ₹986.95 and a low of ₹965.00. Over the past 52 weeks, the stock reached a high of ₹1,324.30 and a low of ₹648.15.
